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BACKGROUND: Detailed insights in temporal evolution of high-sensitivity cardiac troponin following acute coronary syndrome 
(ACS) are currently missing. We aimed to describe and compare the post-ACS kinetics of high-sensitivity cardiac troponin I 
(hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT), and to determine their intra- and interindividual variation in clinically 
stable patients.
METHODS AND RESULTS: We determined hs-cTnI (Abbott) and hs-cTnT (Roche) in 1507 repeated blood samples, derived from 191 
patients with ACS (median, 8/patient) who remained free from adverse cardiac events during 1-year follow-up. Post-ACS kinetics 
were studied by linear mixed-effect models. Using the samples collected in the 6- to 12-month post-ACS time frame, patients 
were then considered to have chronic coronary syndrome. We determined (differences between) the average hs-cTnI and average 
hs-cTnT concentration, and the intra- and interindividual variation for both biomarkers. Compared with hs-cTnT, hs-cTnI peaked 
higher (median 3506 ng/L versus 494 ng/L; P<0.001) and was quicker below the biomarker-specific upper reference limit (16 ver-
sus 19 days; P<0.001). In the post–6-month samples, hs-cTnI and hs-cTnT showed modest correlation (rspearman=0.60), whereas 
the average hs-cTnT concentration was 5 times more likely to be above the upper reference limit than hs-cTnI. The intraindividual 
variations of hs-cTnI and hs-cTnT were 14.0% and 18.1%, while the interindividual variations were 94.1% and 75.9%.
CONCLUSIONS: Hs-cTnI peaked higher after ACS and was quicker below the upper reference limit. In the post–6-month sam-
ples, hs-cTnI and hs-cTnT were clearly not interchangeable, and average hs-cTnT concentrations were much more often above 
the upper reference limit than hs-cTnI. For both markers, the within-patient variation fell largely below beween-patient variation.
REGISTRATION: URL: https://www.trial regis ter.nl; unique identifiers: NTR1698 and NTR1106.
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H igh-sensitivity cardiac troponins (hs-cTns) are now widely used in clinical practice and are key elements of the diagnosis of myocardial infarction (MI) in patients presenting with ischemic chest pain.1,2 In the setting of suspected acute cor-onary syndrome (ACS), high-sensitivity cardiac 
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troponin I (hs-cTnI) and high-sensitivity cardiac tropo-
nin T (hs-cTnT) have a comparable good performance 
and are practically interchangeable.3 However, hs-
cTns are nowadays also measured for purposes 
other than diagnosing ACS, for example, as part of 
perioperative care,4 and studies comparing hs-cTnI 
concentrations and hs-cTnT concentrations outside 
the setting of ACS are scarce and mostly performed 
in the general population.5,6
In the current study, we used the BIOMArCS 
(Biomarker Study to Identify the Acute Risk of a 
Coronary Syndrome) with high-frequency blood sam-
pling,7–9 investigating in detail the evolution of hs-cTnI 
and hs-cTnT concentrations until 1 year after ACS 
admission. We aimed to describe (differences in) the 
post-ACS kinetics, and differences in the hs-cTnI and 
hs-cTnT concentrations after the biomarker reached 
stable levels. In addition, we explored the biological 
variation of cardiac troponins, measured with contem-
porary high-sensitivity assays.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Design
The study design and main results of BIOMArCS has 
been published previously.7–9 In short, BIOMArCS is 
a multicenter, prospective, observational study that 
was conducted in 18 participating hospitals in the 
Netherlands during 2008 to 2015. The study was de-
signed to obtain detailed data on biomarker patterns 
until 1-year follow-up after ACS. Patients >40  years 
old presenting with ACS and at least 1 additional car-
diovascular risk factor were eligible for enrollment. 
Exclusion criteria were ischemia precipitated by a con-
dition other than atherosclerotic chronic coronary syn-
drome (CCS), a left ventricular ejection fraction <30%, 
end-stage congestive heart failure (New York Heart 
Association [NYHA] class ≥3), severe chronic kidney 
disease with measured or calculated glomerular filtra-
tion rate (Cockroft-Gault or Modification of Diet in Renal 
Disease-4 formula) of <30  mL/min per 1.73  m2, or a 
coexistent condition with life expectancy <1  year. All 
patients were treated according to prevailing guide-
lines and at the discretion of the treating physician. The 
study protocol was approved by the institutional review 
boards of the participating hospitals, and all study sub-
jects gave written informed consent.
CLINICAL PERSPECTIVE
What Is New?
• Post–acute coronary syndrome (ACS) kinetics 
differ between high-sensitivity cardiac troponin 
I (hs-cTnI) and high-sensitivity cardiac troponin 
T (hs-cTnT); hs-cTnI peaks higher and is quicker 
below the population upper reference limit than 
high-sensitivity cardiac troponin, and in asymp-
tomatic patients 6  months after ACS, hs-cTnT 
concentrations are far more often above the 
population upper reference limit than measured 
hs-cTnI concentrations.
• Six months after ACS, both hs-cTnI and hs-cTnT 
show little within-patient variability; in contrast, 
the between-patient variation was large.
• Following ACS, patients may have stable el-
evated high-sensitivity cardiac troponin values 
without suffering from a clinical ACS, and such 
individuals may benefit from a patient-specific 
reference value; such an individualized refer-
ence value can be derived using just 2 consec-
utive measurements in the majority of patients.
What Are the Clinical Implications?
• Our high-frequency blood sampling study 
showed that in stable asymptomatic patients 
following ACS, hs-cTnI and hs-cTnT measure-
ments are not interchangeable.
• In stable asymptomatic patients following ACS, 
large between-patient variability exists for hs-
cTnI and hs-cTnT, while the within-patient vari-
ability is relatively small, underlining the clinical 
need for patient-specific reference values for 
high-sensitivity cardiac troponins.
• These patient-specific reference values for 
high-sensitivity cardiac troponins could be of 
help to fine-tune a personalized approach in pa-
tients following ACS, in particular in those with 
elevations that were found by chance (eg, in the 
perioperative setting) and in those presenting 
with unclear symptoms.
Nonstandard Abbreviations and Acronyms
BIOMArCS  Biomarker Study to Identify the 
Acute Risk of a Coronary 
Syndrome
CCS chronic coronary syndrome
CVi  coefficient of intraindidividual or 
within-subject variation
II index of individuality
SWEDEHEART  System for Enhancement and 
Development of Evidence-Based 
Care in Heart Disease Evaluated 
According to Recommended 
Therapies
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Blood Sampling and Storage
Blood samples were collected at admission, at the day 
of hospital discharge, and subsequently every fortnight 
during the first 6 months after discharge. If logistic cir-
cumstances hindered inclusion during hospitalization, 
patients could be included on the first outpatient visit 
within 6 weeks after discharge. In a subset of approxi-
mately 8% of patients, additional blood samples were 
collected within 24, 48, 72, and 96 hours after admis-
sion and at the day of hospital discharge with the spe-
cific aim to study the early evolution and normalization 
of the biomarkers. Follow-up was terminated perma-
nently after coronary artery bypass grafting, hospital 
admission for heart failure, or a deterioration of renal 
function leading to a glomerular filtration rate <30 mL/
min per 1.73 m2.
Blood samples were handled and securely stored 
on-site. After preparation, aliquots were frozen at −80°C 
within 2 hours after withdrawal. Samples were trans-
ported under controlled conditions to the Department 
of Clinical Chemistry at the Erasmus Medical Center 
for long-term storage.
Study Patients
For the BIOMArCS main results analysis, we applied the 
case-cohort approach, including a total of 187 patients, 
of whom 45 reached the study end point of cardiovas-
cular death or repeat ACS.7,8 For the current analysis, we 
excluded these end point cases, and enriched the set 
with 49 patients who had daily sampling during the first 
4 days after the index ACS. Hence, our analysis set con-
sisted of 191 end point–free patients.7 They contributed a 
median of 8 (25th–75th percentile; range, 5–10) repeated 
serum samples per patient (altogether 1507 samples), 
in which hs-cTnI (Abbott Laboratories, Chicago, IL) and 
hs-cTnT (Roche, Basel, Switzerland) were determined in 
a blinded fashion and in 1 batch. These assays have a 
lower limit of detection and population upper reference 
limit (URL; 99th percentile of the distribution in the gen-
eral population) of 1.2 and 26.6 ng/L for hs-cTnI, and 5 
and 14 ng/L for hs-cTnT, respectively. The limit of blank 
was equal to the lower limit of detection for hs-cTnI and 
3.0 ng/L for hs-cTnT. Undetectable concentrations were 
assigned the concentration of 1.0 ng/L for hs-cTnI and 
2.9 ng/L for hs-cTnT.
Statistical Analysis
Continuous variables are presented as mean (SD) or 
median (25th–75th percentile), depending on their dis-
tributions. Categorical variables are summarized as 
numbers and percentages. Differences between hs-
cTnI and hs-cTnT were investigated using McNemar’s 
test for paired nominal data or a Wilcoxon signed-rank 
test for paired continuous data.
Post-ACS Kinetics
We used linear mixed-effect models to describe the 
average cardiac troponin stabilization patterns over 
time. In these models, time was entered as the inde-
pendent variable, and the log-transformed (because 
of the nonnormal distribution) cardiac troponin value 
as the dependent variable. A total of 2 cubic splines 
were placed to model the nonlinearity of the asso-
ciation between time and cardiac troponin concen-
tration. We used Akaike’s information criterion and 
Bayesian information criteria for the optimal placing 
of these splines. Random slopes as well as random 
intercepts were included in the models to allow for 
individual variation.
Using the fitted linear mixed-effect models, we 
calculated the average hs-cTnI and hs-cTnT concen-
trations on a day-to-day basis for each patient. These 
concentrations were then used to estimate the peak 
concentration, the time until peak concentration, the 
median time during which cardiac troponins were el-
evated above the population reference value after the 
index ACS, and the median time until stabilization. We 
defined stabilization as a difference in (model-derived) 
cardiac troponin concentrations of <1% between 2 
consecutive days.
Measures of Biological Variation
For investigating the parameters of variability of a bio-
marker, it is necessary that the patients is in a (bio-
chemically) stable status. On the basis of previous 
studies with repeated echocardiograms and blood 
measurements, we presumed that hs-cTn concen-
trations would be biochemically stable at 6  months 
after ACS.10–12 Accordingly, the analysis of biological 
variation was based on 446 samples (median, 4 sam-
ples per patient [range 3–9] that were collected 6 to 
12 months after the index ACS and was limited to the 
98 patients who had ≥3 measurements in that time 
window and who did not undergo a (staged) percuta-
neous coronary intervention; thus, iatrogenic distortion 
of the cardiac troponin concentrations caused by per-
cutaneous coronary intervention was excluded.13
We determined the coefficient of variation of hs-cTnI 
and hs-cTnT and applied the method of Fraser and 
Harris14 to split the total variation into 3 components. 
These represent the variation attributable to the im-
precision of the analytical process, the intraindividual 
or within-subject variation (CVi) and the interindividual 
or between-subject variation. Coefficient of analytical 
variation can be determined by repeatedly measuring 
the same sample using different assays. However, 
since this procedure is expensive, time consuming, 
and resource draining, laboratories generally use the 
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reference sample. We used the laboratory-specific 
coefficient of analytical variation of 5.0% for hs-cTnI 
and 3.0% for hs-cTnT, respectively. Besides determin-
ing the different coefficients of variability, we also cal-
culated the index of individuality (II) and the reference 
change value for both biomarkers. The II is the ratio 
of the combined within-subject and analytical variation 
relative to the between-subject variation. Previously, 
it was suggested that in case of an II<0.6, individual 
subjects should have their own reference values in-
stead of a population-based reference.15 When the 
II>1.4, a population-based reference is preferred. The 
reference change value reflects the limit of (relative) 
change in biomarker values in individual subjects that 
can be explained by the combined within-subject and 
analytical variation. Finally, we investigated factors as-
sociated with the CVi using linear regression. A more 
detailed description of the parameters of variability 
and the formulas used to calculate them are included 
in Data S1.
Patient-Specific Reference Value
The average time until hs-cTnI and hs-cTnT stabilization 
after the index ACS was <1 month, whereas within-
subject variability was relatively small. Therefore, we 
conducted a post hoc analysis of all 122 patients with 
>3 samples in the >1-month time window to learn if 
a patient-specific reference value could be deter-
mined this early after the index ACS, as follows: We 
calculated the moving average of 2 consecutive hs-
cTn measurements, which was then compared with 
the next measurement. If the difference was <5 ng/L, 
the moving average was then considered the patient-
specific reference. The 5 ng/L threshold was chosen 
because that value was equal to the median patient-
specific hs-cTnT concentration times the upper limit of 
the reference change value.
All analyses were performed using R version 3.1.1 (R 
Foundation for Statistical Computing, Vienna, Austria) 
using packages “nlme”16 and “splines.”17
RESULTS
Baseline Characteristics
Baseline characteristics are presented in Table 1. The 
mean age of the patients in the analysis set was 63.0 
(11.1) years, and 78% were men. More than half of 
the population had hypertension (52.1%) and large 
proportions had hypercholesterolemia (47.5%) and a 
family history of CCS (53.5%). ST-segment–elevation 
MI was the most common index event (46.2%), fol-
lowed by non–ST-segment–elevation MI (40.7%). No 
relevant differences in baseline characteristics were 
identified when comparing the full analysis set with 
the patients used to determine biological variation.
Post-ACS Kinetics
The average concentrations of the different biomark-
ers from the time of the ACS until day 50 are shown 
in Figure 1. Both hs-cTnI and hs-cTnT peaked on day 
1 (median, interquartile range, 1–2) and gradually 
returned to concentrations beneath the population 
URL. The median peak concentration was 3506 ng/L 
(interquartile range, 2300–6596) for hs-cTnI and 
Table 1. Baseline Characteristics
Analysis Set After 6 months
(n=191) (n=98)
Age, y (SD) 62.4 (10.6) 62.8 (9.5)
Male sex, n (%) 148 (77.5) 77 (78.6)
Cardiovascular risk factors, n (%)
Diabetes mellitus 33 (17.3) 17 (17.3)
Hypertension 101 (52.9) 52 (53.1)
Hypercholesterolemia 92 (46.5) 54 (58.2)
Family history of CCS* 87 (53.0) 47 (59.5)
Current smoker 80 (41.9) 41 (41.8)
History of cardiovascular disease, n (%)
MI 50 (26.2) 30 (30.6)
CABG 14 (7.3) 6 (6.1)
PCI 44 (23.2) 28 (28.9)
Stroke 19 (9.9) 7 (7.1)
Admission diagnosis, n (%)
STEMI 93 (49.0) 47 (48.0)
NSTEMI 74 (38.7) 37 (37.8)
UAP 24 (12.6) 14 (14.3)
Physical examination
Body mass index (SD) 27.5 (3.6) 27.5 (3.6)
Killip class 1 (%) 177 (92.7) 94 (95.9)
Heart rate (IQR) 73 (62–84) 70 (61–81)
Systolic blood pressure 
(IQR)
137 (117–152) 136 (119–151)
eGFR, mL/min per 
173 m2 (SD)
98 (30) 97 (28)
Medication, n (%)
Aspirin 183 (96.3) 95 (96.9)
Beta-blocker 167 (87.9) 83 (84.7)
ACEI 138 (72.6) 68 (69.4)
ARB 22 (11.6) 11 (11.2)
Statin 183 (96.3) 96 (98.0)
After 6 months: Analysis set minus an elective PCI >150 days after the 
index event and patients with <3 samples available after 6  months. ACEI 
indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin 
receptor blockers; CABG, coronary artery bypass grafting; CCS, chronic 
coronary syndromes; eGFR, estimated glomerular filtration rate; IQR, 
interquartile range; MI, myocardial infarction; NSTEMI, non–ST-segment–
elevation myocardial infarction; PCI, percutaneous coronary intervention; 
STEMI, ST-segment–elevation myocardial infarction; and UAP, unstable 
angina pectoris. 
*Family history of CCS was defined as angina pectoris, MI, or sudden 
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494 ng/L (397–939) for hs-cTnT (P<0.001). Although 
statistically significant, there was little difference in 
the median time until stabilization on patient level. The 
median number of days was 31 (interquartile range, 
30–32) days for hs-cTnI and 30 (interquartile range, 
30–31) days for hs-cTnT (P<0.001), respectively. In 
contrast, hs-cTnI was quicker below the URL than 
hs-cTnT (median, 16 [13–19] days versus 19 [16–26] 
days; P<0.001).
Biological Variation
Figure 2 depicts all pairs of hs-cTnI and hs-cTnT meas-
urements taken after 6 months. All hs-cTnI values ex-
ceeded the lower limit of detection, whereas 22.0% of 
hs-cTnT values were below the lower limit of detection 
(9.0% below the limits of blank). In all the samples, 
2.0% of hs-cTnI and 17.2% of hs-cTnT values exceeded 
the population URL (P<0.001); 3 patients had an aver-
age hs-cTnI above the URL compared with 16 patients 
with an average hs-cTnT above the URL (P=0.002). 
The Spearman correlation for average hs-cTn level was 
r=0.60 (P<0.001).
The distributions of the hs-cTn measurements after 
6  months are shown for each patient in Figure  3. 
CVis of hs-cTnI and hs-cTnT were 14.0% and 18.1%, 
respectively. We could not identify any baseline 
characteristics that were significantly associated 
with the observed CVis (Table S1). In contrast to the 
small CVis, the coefficients of interindividual or be-
tween-subject variation were large, reflecting rela-
tively large differences in average cardiac troponin 
concentrations between patients. Consequently, 
both biomarkers had IIs <0.6, the reference change 
value limits ranged between −33.6% and 50.5% for 
hs-cTnI, and −39.6% and 65.5% for hs-cTnT, respec-
tively. Consequently, as an example, in a patient with 
a steady-state hs-cTnI concentration of 5 ng/L, a rise 
of 3 ng/L exceeds the combined analytical and with-
in-subject variation with 95% certainty and can thus 
be considered the consequence of pathological pro-
cesses. An overview of the different parameters of 
biological variation is presented in Table 2.
Patient-Specific Reference Value
In the post hoc analysis of 122 patients (see the 
Methods section), a patient-specific reference value 
could be determined in 85.2% (hs-cTnI) and 83.6% 
(hs-cTnT) using the first 2 post-30-day measure-
ments. The median (25th–75th percentile) refer-
ence values were 7.1  ng/L (4.4–10.6) and 8.5  ng/L 
Figure 1. Average stabilization patterns of high-sensitivity cardiac troponins after ACS. The x axes depict the number of 
days since the acute coronary syndrome.
The y axes represent the cardiac troponin concentrations. The left 2 plots are on the log scale with base number 2. A 1-point increase 
can thus be interpreted as a doubling of the value. The black lines depict the cohort average; the dashed lines the corresponding 
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(6.5–12.9) for hs-cTnI and hs-cTnT, respectively. The 
difference between the patient-specific baseline 
value and their last available measurement (on aver-
age 11 months after the index ACS) was <5 ng/L in 
>81.7% (hs-cTnI) and 77.5% (hs-cTnT) of the patients. 
A paired t-test confirmed that there were no signifi-
cant differences between the patient-specific base-
line value on the basis of the first 2 measurements 
and the last available measurement for both hs-cTnI 
(mean difference, −0.37 ng/L; 95% CI, −3.26–2.53; 
P=0.80) and hs-cTnT (mean difference, 0.11  ng/L; 
95% CI, −1.81–2.03; P=0.91).
DISCUSSION
In BIOMArCS, we confirmed the hs-cTn peak, the pla-
teau after the index ACS, and that values can remain 
above the population URL for a prolonged time.18 We 
added that after a quick decrease, the median time to 
reach values below the URL was shorter for hs-cTnI 
than for hs-cTnT. In addition, post-6-month samples 
in (then) stable patients with CCS, the percentage of 
hs-cTnT measurements with concentration above the 
population URL was far greater than that of hs-cTnI 
(Figure  3) with (thus) poor interchangeability of the 2 
biomarkers. The individual variation of both hs-cTnI 
and hs-cTnT were low, while differences between 
patients were large. This combination of characteris-
tics led to a low II (<0.6) for both cardiac troponins, 
which again stresses that in patients with known stable 
CCS after having previously endured an ACS, patient-
specific reference values are to be preferred over the 
population-based reference.15 Finally, we were able to 
demonstrate that the patient-specific reference value 
can already be obtained on the basis of 2 consecu-
tive samples taken after 1 month in the vast majority of 
subjects following ACS.
In our study, we found some striking differences 
between hs-cTnI and hs-cTnT. After the index ACS, 
hs-cTnI showed a higher peak concentration and had 
a quicker descent when compared with hs-cTnT. The 
higher peak levels had been previously described by 
Laugaudin et al in 106 consecutive patients with ST-
segment–elevation MI.19 We now add to this that hs-cTnI 
is also faster below the population URL than hs-cTnT. 
After 6 months, when patients were to be considered 
biochemically stable, there were >5 times as many pa-
tients with an average hs-cTnT concentration above the 
Figure 2. Comparison of high-sensitivity cardiac troponin 
I and T concentrations in the samples taken after 6 months.
The x axis depict the hs-cTnI concentration, while on the y axis 
the concentration of hs-cTnT is given. Each dot represents a 
single blood sample in which thus both an hs-cTnI and hs-
cTnT concentration has been measured. hs-cTnI indicates 
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Figure 3. Distribution of the high-sensitivity cardiac troponins after 6 months. On the horizontal axes are the individual 
patients ranked based on their average cardiac troponin values.
The vertical axes depict the cardiac troponin concentrations resulting from the repeated measurements. The dotted lines show the 
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population URL than patients with hs-cTnI above the 
population URL. Moreover, despite being statistically 
significant, the correlation between average hs-cTnI 
and hs-cTnT concentration clearly showed that the 2 
markers cannot be considered interchangeable in an 
asymptomatic post-ACS population. Although obvious 
differences in design (single measurement versus mul-
tiple measurements) and participants (general popula-
tion versus patients with ACS) are to be acknowledged, 
our findings are much in line with previous reports from 
general population cohorts comparing hs-cTns. In a 
study by Kimenai et al among 1540 individuals without 
significant baseline disease, the correlation coefficient 
between hs-cTnI and hs-cTnT was 0.55,6 while among 
19 501 participants of the General Scotland Scottisch 
Family Health Study, the r was 0.46.5 Remarkably, 
in the latter study, the number of patients above the 
population URL was much greater for hs-cTnT than 
for hs-cTnI, which is in line with our results. We add to 
this current body of evidence that also in patients with 
known CCS the correlation between hs-cTnI and hs-
cTnT concentrations are not strong.
To date, studies on the biological variation of cardiac 
troponins, measured with contemporary high-sensi-
tivity assays, are scarce, and their sample sizes have 
usually been small.20–24 Particularly in patients with es-
tablished CCS, such as patients following ACS, little 
to no information is available. The parameters of vari-
ation found in our study are comparable to earlier re-
ports in subjects sampled from the general “healthy” 
population. For example, Wu et al23 reported a long-
term individual variation of 14% for hs-cTnI based on 
17 healthy subjects. The coefficient of interindividual 
or between-subject variation in their report was lower 
than in our study, which suggests that cardiac tro-
ponins show larger variations in patients with CCS 
than in healthy individuals. The larger between-subject 
variation in a diseased population compared with a 
healthy one is also confirmed by a study of Meijers et 
al25 comparing biological variation in 83 patients with 
heart failure to 28 healthy subjects. They reported a 
coefficient of interindividual or between-subject varia-
tion for hs-cTnT of 96.6% and 51.2%, respectively. The 
CVis, however, were similar in both populations and 
comparable to our cohort.
We were able to demonstrate the feasibility of ob-
taining patient-specific references values in patients 
with established CCS. This reference value could be 
retrieved in the majority of our patients following ACS 
based on a limited number of consecutive measure-
ments, whereas these values showed good agreement 
with samples taken later during follow-up. It is our opin-
ion that the patient-specific reference value can help 
fine-tune the diagnostic process in specific situations. 
These reference values could be of help to fine-tune 
a personalized approach in patients following ACS, in 
particular in those with asymptomatic elevations that 
were found by chance (eg, hs-cTn measurements in 
the perioperative setting) and in those presenting with 
unclear symptoms. For instance, if a patient comes 
with atypical complaints and has slightly elevated hs-
cTn concentrations in 2 consecutive measurements. 
Atypical presentations are not uncommon,26 and a rise 
of hs-cTns concentrations cannot always be identified, 
particularly if patients come several hours after the 
complaints start when cardiac troponin levels might 
already be in the plateau phase. Comparing the hs-cTn 
concentrations measured with the patient-specific ref-
erence could help determine if this patient is more likely 
to have an ACS and needs to go to the catheterization 
laboratory or can be sent home. Also, when a patient 
has typical complaints but the hs-cTn concentrations 
are still below population URL with a borderline rise 
between the 2 consecutive measurements, comparing 
the concentration with their individual reference value 
might determine the final decision. If the found con-
centration is (much) higher than the patient-specific 
reference value (but still below population URL), then 
it is probably more likely to be unstable angina pecto-
ris or an MI. Accurately diagnosing unstable angina is 
important, as these patients often need early percu-
taneous coronary intervention and have an incidence 
rate of future (lethal) cardiac events comparable with 
patients who had a non–ST-segment–elevation MI.27,28 
Moreover, particularly when using hs-cTnI, MI is known 
to be underdiagnosed because of the relatively high 
population URL.29
Limitations
The high-frequency blood sampling design of 
BIOMArCS enables an in-depth analysis of lon-
gitudinal biomarker patterns in the population of 
patients with established CCS. A limitation of the 
Table 2. Overview of Parameters of Biological Variation
Average Patient 
Concentration (ng/mL) CVa (%) CVi (%) CVg (%) II RCV (%)
Log-Normal
RCV Low (%) RCV Up (%)
hs-cTnI 5.3 (3.7–8.3) 5.0 14.0 94.1 0.16 38.7 −33.6 50.5
hs-cTnT 7.8 (5.1–11.1) 3.0 18.1 75.9 0.24 50.1 −39.6 65.5
CVa indicates analytical coefficient of variation; CVg, interindividual coefficient of variation; CVi, intraindividual coefficient of variation; Hs-cTnI, high-sensitivity 
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current analysis is that compared with a real-world 
ACS population such as the SWEDEHEART (System 
for Enhancement and Development of Evidence-
Based Care in Heart Disease Evaluated According 
to Recommended Therapies) registry,30 the subjects 
included in the current study were on average 8 years 
younger, were more likely to have an ST-segment–
elevation MI (49% versus 35.5%), had more previ-
ous percutaneous coronary interventions performed 
(29.1% versus 13.8%), and had a lower prevalence 
of diabetes mellitus (17.3% versus 22.5%). These dif-
ferences might compromise the generalizability of 
the results. Moreover, the generalizability of our pa-
rameters could potentially be further compromised 
as per study protocol; we excluded all patients with 
recurrent events during the 1-year follow-up, as we 
did not want to take into account possible distortion 
from an imminent ischemic event while calculating 
the parameters of variability. However, in a sensitivity 
analysis also comprising the patients with ischemic 
events, the parameters changed only marginally (data 
not shown). Second, information on the patient’s ac-
tivities before sampling is lacking and that the timing 
of blood sampling during the day was not specified. 
Hs-cTns are known to be influenced by (heavy) physi-
cal activity,31 and hs-cTnT, but not hs-cTnI, is known 
to exhibit a diurnal rhythm.32 However, we have in-
vestigated the variation of the time of sampling and 
found that all measurements were taken between 8 
am and 4 pm. Moreover, we observed that, although 
not specified in the protocol, the vast majority of the 
patients had repeated visits for blood sampling at the 
same hour of the day. Hence, the within-patient vari-
ation in biomarker concentrations found in this study 
cannot be explained by variations in sampling time. 
Third, no echocardiographic data are available, which 
could have been an aid in explaining chronic elevated 
cardiac troponin concentrations in different patients. 
A final limitation is that, using our data, although plau-
sible, we cannot confirm that using a patient-specific 
reference value enhances the diagnostics for future 
ACS. This should be the focus of future research.
CONCLUSIONS
In conclusion, hs-cTn concentrations showed similar 
post-ACS kinetics; however, after the initial peak, hs-
cTnI had a quicker median time to concentrations below 
population URL than hs-cTnT. In the post-6-month sam-
ples, hs-cTnI and hs-cTnT showed modest correlation 
(rspearman=0.60), whereas the average hs-cTnT concen-
tration was 5 times more likely to be above the URL than 
hs-cTnI. The within-patient variation was small for both 
cardiac troponins and comparable to healthy popula-
tions. Between-patient variation, however, is much 
higher in post-ACS patients than in population controls. 
Consequently, our data support the use of patient-spe-
cific reference values for hs-cTn in patients with CCS. 
Patient-specific reference values can easily be obtained 
in the vast majority of patients by using 2 consecutive 
samples during a clinically stable phase.
APPENDIX
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the Netherlands; Rene Dijkgraaf, St. Jansdal Hospital, 
Harderwijk, the Netherlands; S. Hong Kie; Treant 
Zorggroep, Bethesda, Hoogeveen, the Netherlands; 
Alexander J. Wardeh, Medisch Centrum Haaglanden 
location Westeinde, Den Haag, the Netherlands; 
Walther Hermans, Elizabeth-Tweesteden Hospital, 
Tilburg, the Netherlands; Etienne Cramer, Radboud 
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Data S1.
Supplemental Methods 
The CVi was defined as the median value of the CVs of the repeated measurements in 
individual subjects (CVsubject), adjusted for the analytical variation: 
CVi = √median(CVsubject
2 ) − CVa
2
Finally, CVg was determined as 100% times the standard deviation (sdX̅subject) of the mean values of the
repeated measurements in individual subjects (X̅subject) by the (unweighted) mean of these means 
(X̅group): 
CVg = 100% ∗ sdX̅subject X̅group⁄
The Index of Individuality (II) is the ratio of the combined within-subject and analytical variation relative 




When the II <0.6, it is agreed that subjects should have their own reference values, based on previous 
samples.17 When the II >1.4, a population-based reference is preferred. 
The Reference Change Value (RCV) reflects the limit of (relative) change in biomarker values in individual 
subjects that can be explained by the combined within-subject and analytical variation. For biomarkers 
with a normal distribution, the RCV can be calculated as follows: 
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where Zα 2⁄  represents the critical value of the normal distribution for 100% ∗ (1 − α) 2⁄  confidence. 
For biomarkers with a skewed distribution a log-normal approach has been described,18 and the RCV 
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value estimate (95%CI) 
P-
value 
0.002 (-0.686, 0.691) 0.994 -0.064 (-0.669, 0.541) 0.834
-0.01 (-0.04, 0.02) 0.503 -0.022 (-0.048, 0.003) 0.088
0.072 (-0.501, 0.645) 0.804 -0.15 (-0.652, 0.352) 0.555 
-0.53 (-1.269, 0.209) 0.158 -0.213 (-0.867, 0.441) 0.519
-0.01 (-0.576, 0.556) 0.972 0.192 (-0.303, 0.688) 0.443 
0.094 (-0.474, 0.662) 0.744 -0.17 (-0.668, 0.328) 0.5 
-0.061 (-0.633, 0.511) 0.832 0.193 (-0.379, 0.765) 0.503 
-0.029 (-0.108, 0.05) 0.467 -0.032 (-0.101, 0.038) 0.368
0.004 (-0.013, 0.021) 0.637 -0.005 (-0.02, 0.009) 0.485 
-0.001 (-0.012, 0.009) 0.842 -0.002 (-0.011, 0.007) 0.702
0.782 (-0.859, -2.544) 0.947 0.52 (-0.92, -2.254) 0.717 
0.516 (-1.122, 2.153) 0.533 0.556 (-0.881, 1.992) 0.445 
-0.726 (-1.497, 0.045) 0.065 0.088 (-0.601, 0.777) 0.8 
0.059 (-0.555, 0.672) 0.85 -0.04 (-0.579, 0.498) 0.882 
0.294 (-0.599, 1.188) 0.515 0.088 (-0.698, 0.874) 0.824 
Male sex 
Age, y 




Family history of CAD, yes 
BMI 
Heart Rate 






Statin -1.864 (-3.827, 0.099) 0.062 -0.326 (-2.081, 1.428) 0.713
Betas for increase/decrease in Cvi for the different baseline characteristics 
95%CI: 95% confidence interval; Y: year; CAD: coronary artery disease; BMI: body Mass Index: 
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